Agenus has lined up as much as $340 million through an equity raising to finance a planned late-stage trial of its colon cancer treatment. The Lexington, Mass., immuno-oncology company said Monday it ...
10hon MSN
Why is Agenus stock gaining Monday?
Agenus Inc. AGEN reported updated three-year Phase 1b data showing durable survival with its botensilimab plus balstilimab ...
Agenus (NASDAQ:AGEN) said it is shifting its development focus and financial resources toward a Phase 3 registrational trial ...
Agenus has scrapped a phase 3 study of its combo therapy in colorectal cancer after just three months in order to go all-in ...
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that it has entered into a securities purchase agreement for a private placement of approximately $85 million in ...
Pembrolizumab plus enfortumab vedotin is now approved for all adults with muscle-invasive bladder cancer undergoing cystectomy.
The US Food and Drug Administration (FDA) has approved two of Merck & Co's (MSD) Keytruda (pembrolizumab) and Keytruda Qlex ...
The FDA has approved two immunotherapy combination therapies for adults with muscle-invasive bladder cancer. Pembrolizumab ...
The FDA approved pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa (Keytruda Qlex) in combination with ...
The platinum-free combination significantly improved EFS, OS, and pathologic complete response rates compared with standard neoadjuvant gemcitabine/cisplatin.
On Friday, the U.S. Food and Drug Administration (FDA) approved Pfizer Inc.’s PFE and Astellas Pharma Inc.’s ALPMF ALPMY ...
The increasingly more popular combination of Padcev and Keytruda has expanded its bladder cancer territory once again. | The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results